Cargando…

Atypical Mechanism of Glucose Modulation by Colesevelam in Patients with Type 2 Diabetes

Colesevelam’s glucose-lowering mechanism of action is not completely understood. Clinical trials of colesevelam suggest that its mechanism, and often adverse effects, differ from those of other oral antidiabetes drugs. Colesevelam does not affect insulin sensitivity (unlike thiazolidinediones), insu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nwose, Oliseyenum M., Jones, Michael R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864737/ https://www.ncbi.nlm.nih.gov/pubmed/24348081 http://dx.doi.org/10.4137/CMED.S12590

Ejemplares similares

Role of Colesevelam in Combination Lipid-Lowering Therapy
por: Jones, Michael R., et al.
Publicado: (2013)

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence
por: Fonseca, Vivian A, et al.
Publicado: (2010)

Effect of Colesevelam HCl Monotherapy on Lipid Particles in Type 2 Diabetes Mellitus
por: Rosenson, Robert S., et al.
Publicado: (2014)

Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action
por: Zema, Michael James
Publicado: (2012)

Colesevelam hydrochloride: A novel agent in patients with type 2 diabetes
por: Sekhri, Kavita, et al.
Publicado: (2011)

Glucose and Low-Density Lipoprotein Cholesterol Lowering in Elderly Patients with Type 2 Diabetes: Focus on Combination Therapy with Colesevelam HCl
por: Marrs, Joel C.
Publicado: (2012)

Colesevelam‐induced hypoglycaemia in a patient with type 1 diabetes mellitus
por: Pavlou, Panagiotis, et al.
Publicado: (2021)

Safety and Efficacy of Colesevelam HCl in the Treatment of Elderly Patients
por: Gavin, James R., et al.
Publicado: (2014)

Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors
por: Bays, Harold, et al.
Publicado: (2007)

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
por: Fonseca, Vivian A., et al.
Publicado: (2008)

Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
por: Sonnett, Travis, et al.
Publicado: (2010)

Colesevelam Improves Oral but Not Intravenous Glucose Tolerance by a Mechanism Independent of Insulin Sensitivity and β-Cell Function
por: Marina, Anna L., et al.
Publicado: (2012)

Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
por: Hartmann, Phillipp, et al.
Publicado: (2022)

Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
por: Bays, Harold E
Publicado: (2012)

The analysis of gut microbiota in patients with bile acid diarrhoea treated with colesevelam
por: Kumar, Aditi, et al.
Publicado: (2023)

Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
por: Rosenbach, Kevin, et al.
Publicado: (2023)

Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective
por: Goldberg, Ronald B
Publicado: (2009)

Effectiveness and Tolerability of Colesevelam HCl for Accelerated Elimination of Teriflunomide in Healthy Participants
por: Lunven, Catherine, et al.
Publicado: (2017)

Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice
por: Cabré, Noemí, et al.
Publicado: (2021)

Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development
por: Zhou, Enchen, et al.
Publicado: (2020)

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids
por: Fuchs, Claudia Daniela, et al.
Publicado: (2018)

Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record
por: Hansen, Richard A, et al.
Publicado: (2013)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

Modulation of Glucose Transporter Protein by Dietary Flavonoids in Type 2 Diabetes Mellitus
por: Hajiaghaalipour, Fatemeh, et al.
Publicado: (2015)

Blood Viscosity, Lipid Profile and Lipid Peroxidation in Type-1 Diabetic Patients with Good and Poor Glycemic Control: The Promise and Reality
por: Nwose, Ezekiel Uba
Publicado: (2013)

Laboratory evaluations to optimize outcomes of antioxidant nutrition therapy in diabetes management
por: Nwose, Ezekiel Uba
Publicado: (2009)

The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus
por: Dong, Meiyuan, et al.
Publicado: (2023)

The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms
por: Massimino, Elena, et al.
Publicado: (2021)

Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis
por: Gallieni, Maurizio, et al.
Publicado: (2021)

The methodology of glucose monitoring in type 2 diabetes mellitus
por: GRIBOVSCHI, MIHAELA
Publicado: (2013)

Atypical functions of xenobiotic receptors in lipid and glucose metabolism
por: Wang, Jingyuan, et al.
Publicado: (2022)

Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation
por: Bryk-Wiązania, Agata Hanna, et al.
Publicado: (2021)

A review of flash glucose monitoring in type 2 diabetes
por: Krakauer, Marcio, et al.
Publicado: (2021)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
por: Kim, Yoojin, et al.
Publicado: (2012)

Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes
por: Handelsman, Yehuda
Publicado: (2019)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris, Kira, et al.
Publicado: (2018)

Effect of eating vegetables before carbohydrates on glucose excursions in patients with type 2 diabetes
por: Imai, Saeko, et al.
Publicado: (2014)

Bile Acid Sequestration via Colesevelam Reduces Bile Acid Hydrophobicity and Improves Liver Pathology in Cyp2c70(−/−) Mice with a Human-like Bile Acid Composition
por: Palmiotti, Anna, et al.
Publicado: (2023)

An atypical presentation of type 1 diabetes
por: Knopp, Brandon W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_74uu4i16f3bif3gu6k0v9vva21